Less than two weeks after posting a scathing Form 483 filing, the FDA slammed Chinese API maker Sichuan Deebio Pharmaceuticals with a warning letter (PDF) citing “significant deviations” in its ...
当前正在显示可能无法访问的结果。
隐藏无法访问的结果当前正在显示可能无法访问的结果。
隐藏无法访问的结果